Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1518-1523

  Perera, Ayesh D ^a   Kleymenova, Elena V ^a   Walker, Cheryl L ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; PROTEIN P27; TRANSFORMING GROWTH FACTOR ALPHA RECEPTOR;

ARTICLE; AUTOCRINE EFFECT; CANCER INHIBITION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; GENE INACTIVATION; GENE TARGETING; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR BLOCKING; TUMOR SUPPRESSOR GENE;

ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL COUNT; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; LIGASES; MICROTUBULE-ASSOCIATED PROTEINS; MUTATION; PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0034089164     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. DeKiernion, J. B., and Belldegrun, A. Renal tumors. In: M. F. Campbell, A. B. Retik, E. Vaughn, and P. C. Walsh (eds.), Campbell's Urology, 6th ed., pp. 1053-1093. Philadelphia, 1993.
2. Finney, R. The value of radiotherapy in the treatment of hypernephroma: a clinical trial. Br. J. Urol., 45: 258-269, 1973.
3. Yagoda, A., Abi-Rached, B., and Petrylak, D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin. Oncol., 22: 42-60, 1995.
4. Figlin, R. A. Renal cell carcinoma: management of advanced disease. J. Urol., 161: 381-386, 1999.
5. Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F. M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., Schmidt, L., Zhou, F., Li, M., Wei, M. H., Chen, F., Glenn, G., Choyke, P., Walther, M. M., Weng, Y., Duar, D. R., Dean, M., Glavac, D., Richards, F. M., Crossey, P. A., Ferguson-Smith, M. A., Paslter, D. L., Chumakov, I., Cohen, D., Chinault, A. G., Maher, E. R., Linehan, W. M., Zbar, B., and Lerman, M. I. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (Washington DC), 260: 1317-1320, 1993.
6. Kenck, C., Wilhelm, M., Bugert, P., Staehler, G., and Kovacs, G. Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J. Pathol., 179: 157-161, 1996.
7. Foster, K., Prowse, A., van den Berg, A., Fleming, S., Hulsbeek, M. M., Crossey, P. A., Richards, F. M., Cairns, P., Affara, N. A., Ferguson-Smith, M. A., Buys, C. H. M., and Maher, E. R. Somatic mutations of the von Hippel-Lindau disease tumor suppressor gene in non-familial clear cell renal carcinoma. Hum. Mol. Genet., 3: 2169-2173, 1994.
8. Jiang, F., Richter, J., Schraml, P., Bubendorf, L., Gasser, T., Sauter, G., Mihatsch, M. J., and Moch, H. Chromosomal imbalances in papillary renal cell carcinoma. Am. J. Pathol., 153: 1467-1473, 1998.
9. nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene, 15: 2233-2239, 1997.
10. Schwerdtle, R. F., Storkel, S., Neuhaus, C., Brauch, H., Weidt. E., Brenner, W., Hohenfellner, R., Huber, C., and Decker, H-J. Allelic losses at chromosomes 1p, 2p, 6p, 10p, 13q, 17p, and 21q significantly correlate with the chromophobe subtype of renal cell carcinoma. Cancer Res., 56: 2927-2930, 1996.
11. Wu, J., Caliendo, G., Hu, X. P., and Dutcher, J. P. Impact of histology on the treatment outcome of metastatic or recurrent renal cell carcinoma. Med. Oncol., 15: 44-49, 1998.
12. Freeman, M. R., Washecka, R., and Chung, L. W. Aberrant expression of epidermal growth factor receptor and HER-2 (erbB-2) messenger RNAs in human renal cancers. Cancer Res., 49: 6221-6225, 1989.
13. Mydlo, J. H., Michaeli, J., Cordon-Cardo, C., Goldenberg, A. S., Heston, W. D., and Fair, W. R. Expression of transforming growth factor α and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res., 49: 3407-3411, 1989.
14. Salomon, D. S., Brandt, R., Ciardiello, F., and Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol., 19: 183-232, 1995.
15. Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Pomatico, G., Pepe, S., Bianco, A. R., Agrawal, S., Mendelsohn, J., and Tortora, G. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. J. Natl. Cancer Inst., 90: 1087-1094, 1998.
16. Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., Radinsky, R., and Dinney, C. P. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res., 5: 257-265, 1999.
17. Cip1 in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin. Cancer Res., 3: 1943-1948, 1997.
18. 1 arrest in prostatic cancer cell line DU145. Cancer Res., 56: 3666-3669, 1996.
19. Prewett, M., Rothman, M., Waksal, H., Feldman, M., Bander, N. H., and Hicklin, D. J. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin. Cancer Res., 4: 2957-2966, 1998.
20. Kawamoto, T., Sato, J. D., Le, A., Polikoff, J., Sato, G. H., and Mendelsohn, J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc. Natl. Acad. Sci. USA, 80: 1337-1341, 1983.
21. Goldstein, N. I., Prewett, M., Zuklys, K., Rockwell, P., and Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res., 1: 1311-1318, 1995.
22. Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F. M., Lubensky, L., Duar, D. R., Florence, C., Pozzatti, R., Walther, M. M., Bander, N. H., Grossman, H. B., Brauch, M., Porner, S., Brooks, J. D., Isaacs, W. B., Lerman, M. I., Zbar, B., and Linehan, W. M. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet., 7: 85-90, 1994.
23. Gnarra, J. R., Zhou, S., Merrill, M. J., Wagner, J. R., Krumm, A., Papavassiliou, E., Oldfield, E. H., Klausner, R. D., and Linehan, W. M. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl. Acad. Sci. USA, 93: 10589-10594, 1996.
24. Derynck, R., Roberts, A. B., Winkler, M. E., Chen, E. Y., and Goeddel, D. V. Human transforming growth factor-α: precursor structure and expression in E. coli. Cell, 38: 287-297, 1984.
25. Simmen, F. A., Gope, M. L., Schulz, T. Z., Wright, D. A., Carpenter, G., and O'Malley, B. W. Isolation of an evolutionarily conserved epidermal growth factor receptor cDNA from human A431 carcinoma cells. Biochem. Biophys. Res. Commun., 124: 125-132, 1984.
26. Pause, A., Lee, S., Lonergan, K. M., and Klausner, R. D. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc. Natl. Acad. Sci. USA, 95: 993-998, 1998.
27. Atlas, I., Mendelsohn, J., Baselga, J., Fair, W. R., Masui, H., and Kumar, R. Growth regulation of human renal carcinoma cells: role of transforming growth factor α. Cancer Res., 52: 3335-3339, 1992.
28. Ramp, U., Jaquet, K., Reinecke, P., Schardt, C., Friebe, U., Nitsch, T., Marx, N., Gabbert, H. E., and Gerharz, C. D. Functional intactness of stimulatory and inhibitory autocrine loops in human renal carcinoma cell lines of the clear cell type. J. Urol., 157: 2345-2350, 1997.
29. Kaelin, W. G., Iliopoulos, O., Lonergan, K. M., and Ohh, M. Functions of the von Hippel-Lindau tumour suppressor protein. J. Intern. Med., 243: 535-539, 1998.
30. Duan, D. R., Pause, A., Burgess, W. H., Aso, T., Chen, D. Y., Garrett, K. P., Conaway, R. C., Conaway, J. W., Linehan, W. M., and Klausner, R. D. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science (Washington DC), 269: 1402-1406, 1995.
31. Kibel, A., Iliopoulos, O., DeCaprio, J. A., and Kaelin, W. G., Jr. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science (Washington DC), 269: 1444-1446, 1995.
32. Kamura, T., Sato, S., Haque, D., Liu, L., Kaelin, W. G., Jr., Conaway, R. C., and Conaway, J. W. The elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev., 12: 3872-3881, 1998.
33. Mukhopadhyay, D., Knebelmann, B., Cohen, H. T., Ananth, S., and Sukhatme, V. P. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol. Cell. Biol., 17: 5629-5639, 1997.
34. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene, 12: 1397-1403, 1996.